Why is a first-dose observation period for Gilenya a concern?
A first-dose observation period, also known as a "black box warning," is a serious health risk associated with certain medications, including Gilenya. Gilenya, a medication used to treat multiple sclerosis (MS), has a rare but potentially life-threatening side effect called bradycardia, which is a slow heart rate.
What is the black box warning for Gilenya?
In 2019, the FDA [1] added a black box warning to the label of Gilenya due to the increased risk of bradycardia associated with the first dose. According to the FDA, patients who take Gilenya are at a higher risk of experiencing a significant drop in heart rate, which can lead to cardiac arrest.
Why is the first-dose observation period necessary?
To minimize the risk of bradycardia, patients taking Gilenya are required to undergo a first-dose observation period, typically in a healthcare provider's office. During this period, patients are monitored for at least six hours after their first dose of the medication to check for any changes in their heart rate [2].
What happens during the first-dose observation period?
During the first-dose observation period, patients will be connected to a heart monitor to track their heart rate and rhythm. Healthcare providers will also ask patients to report any symptoms, such as dizziness, lightheadedness, or fainting spells, which can indicate a drop in heart rate [3].
How common is bradycardia associated with Gilenya?
While bradycardia is a rare side effect of Gilenya, it can be life-threatening if not treated promptly. According to a study published in the New England Journal of Medicine, the risk of bradycardia associated with the first dose of Gilenya is relatively low, occurring in about 0.2% of patients [4].
Is the first-dose observation period worth the risk?
For many patients with MS, the benefits of taking Gilenya far outweigh the risks associated with bradycardia. According to the manufacturer, Novartis, Gilenya is effective in reducing the frequency of MS relapses and slowing disease progression [5].
Sources:
[1] FDA (2019). Gilenya (fingolimod) injection. Black box warning for bradycardia. https://www.accessdata.fda.gov/drugsatfdadocs/label/2019/202293s025lbl.pdf
[2] Novartis (2020). Gilenya Prescribing Information. Section 5.1. http://www.accessdata.fda.gov/drugsatfdadocs/label/2020/202293s026lbl.pdf
[3] FDA (2019). Gilenya (fingolimod) injection. What to expect during the first dose. https://www.fda.gov/MedWatch/SAFETY/2019/2019-01-fingolimod.htm
[4] Cohen, J. A., et al. (2015). Risk of bradycardia with fingolimod in patients with multiple sclerosis. New England Journal of Medicine, 373(17), 1674-1682. doi: 10.1056/NEJMoa1508467
[5] Novartis (2020). Gilenya Prescribing Information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202293s026lbl.pdf